Table 3.
Medications of patients who underwent CTO-PCI.
| Variable | Failed CTO-PCI (n = 48) | Successful CTO-PCI (n = 252) | p-value | ||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Medications | |||||
| Adenosine | 1 | 2.1 | 2 | 0.8 | 0.41 |
| Aspirin | 5 | 10.4 | 13 | 5.2 | 0.16 |
| Atropine | 1 | 2.1 | 6 | 2.4 | 0.90 |
| Bivalirudin | 1 | 2.1 | 0 | 0 | 0.022* |
| Ticagrelor | 3 | 6.3 | 24 | 9.5 | 0.47 |
| Piritramide | 0 | 0.0 | 1 | 0.4 | 0.66 |
| Urapidil | 0 | 0.0 | 7 | 2.8 | 0.24 |
| Prasugrel | 0 | 0.0 | 7 | 2.8 | 0.24 |
| Fentanyl | 0 | 0.0 | 1 | 0.4 | 0.66 |
| GP IIb/IIIa inhibitor | 3 | 6.3 | 4 | 1.6 | 0.050 |
| Isoptin | 2 | 4.2 | 33 | 13.1 | 0.077 |
| Furosemide | 1 | 2.1 | 3 | 1.2 | 0.62 |
| Nitroglycerine | 9 | 18.8 | 138 | 54.8 | <0.001* |
| Nitropohl infusion pump | 1 | 2.1 | 1 | 0.4 | 0.19 |
| Clopidogrel | 7 | 14.6 | 41 | 16.3 | 0.77 |
| Propofol | 5 | 10.4 | 13 | 5.2 | 0.16 |
| Protamine sulfate | 2 | 4.2 | 0 | 0 | <0.001* |
| PSP/Valium | 2 | 4.2 | 3 | 1.2 | 0.14 |
| Sedacorone | 1 | 2.1 | 2 | 0.8 | 0.41 |
| Epinephrine | 1 | 2.1 | 3 | 1.2 | 0.62 |
| Morphine | 15 | 31.3 | 4 | 1.6 | 0.49* |
| Norepinephrine | 4 | 8.3 | 0 | 0.0 | 0.008* |
| Mean heart rate (±SD) | 69.4 | ±11.4 | 69.2 | ±12.2 | 0.90 |
| Alpha-blocker | 1 | 2.1 | 11 | 4.4 | 0.46 |
| Beta-blocker | 40 | 83.3 | 219 | 86.9 | 0.51 |
| Calcium channel blocker | 9 | 18.8 | 43 | 17.1 | 0.78 |
| ACEi or ARB | 42 | 87.5 | 203 | 80.6 | 0.25 |
| Diuretic | 20 | 41.7 | 93 | 36.9 | 0.53 |
| Entresto | 0 | 0 | 4 | 1.6 | 0.38 |
| Aldosterone antagonist | 4 | 8.3 | 39 | 15.5 | 0.20 |
| Proton pump inhibitor | 33 | 68.8 | 137 | 54.4 | 0.065 |
| Statin | 0.29 | ||||
| None | 5 | 10.4 | 30 | 11.9 | |
| Low/normal dose | 20 | 41.7 | 76 | 30.2 | |
| High dose | 23 | 47.9 | 146 | 57.9 | |
| Sedacoron | 1 | 2.1 | 6 | 2.4 | 0.90 |
| Antianginal drug | 23 | 47.9 | 72 | 28.6 | 0.008* |
| Aspirin | 46 | 95.8 | 250 | 99.2 | 0.062 |
| DAPT medication | <0.001* | ||||
| Clopidogrel | 25 | 52.1 | 161 | 64.1 | |
| Prasugrel | 6 | 12.5 | 20 | 8.0 | |
| Ticagrelor | 10 | 20.8 | 68 | 27.1 | |
| Other | 7 | 14.6 | 2 | 0.8 | |
| DAPT duration | <0.001* | ||||
| 1 month | 0 | 0 | 1 | 0.4 | |
| 3 months | 3 | 6.3 | 4 | 1.6 | |
| 6 months | 3 | 6.3 | 12 | 4.8 | |
| 12 months | 26 | 54.2 | 223 | 88.5 | |
| 24 months | 2 | 4.2 | 3 | 1.2 | |
| Other | 14 | 29.0 | 9 | 3.5 | |
| Triple therapy | 5 | 10.4 | 30 | 12.0 | 0.76 |
| Oral anticoagulant | 6 | 12.5 | 34 | 13.5 | 0.85 |
| Type of oral anticoagulant | |||||
| No anticoagulant | 42 | 87.5 | 219 | 86.9 | |
| Apixaban | 1 | 2.1 | 8 | 3.2 | |
| Dabigatran | 0 | 0 | 2 | 0.8 | |
| Edoxaban | 0 | 0 | 1 | 0.4 | |
| Rivaroxaban | 3 | 6.3 | 14 | 5.6 | |
| VKA | 2 | 4.2 | 8 | 3.2 | |
SD, standard deviation; DAPT, dual antiplatelet therapy; VKA, vitamin K antagonist. *p < 0.05.